2014 Fiscal Year Final Research Report
A novel chemotherapy of malignant glioma by concomitant use of inhibitors for angiogenetic factor and hypoxia-inducible factor
| Project/Area Number |
24592178
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Fujita Health University |
|---|
Principal Investigator |
HAYASHI Takuro 藤田保健衛生大学, 医学部, 客員講師 (40296611)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HIROSE Yuichi 藤田保健衛生大学, 医学部, 教授 (60218849)
ITO Keisuke (70622934)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Keywords | malignant glioma / bevacizumab / rapamycin / angiogenesis / hypoxia / xenograft |
|---|
| Outline of Final Research Achievements |
Using human glioma cell line U251, biological responses of glioma cells to combination usage of angiogenesis inhibitor (bevacizumab) and chemotherapeutic agent (rapamycin) was investigated in vitro and in vivo. The result of this study suggested that the growth of glioma might be inhibited by rapamycin,which blocked the secondary angiogenesis, resulted from hypoxic state by bevacizumab. Thus, this type of concomitant therapy could be one of the novel approaches of malignant glioma.
|
| Free Research Field |
neurooncology
|
